Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19.
Trends Pharmacol Sci
; 41(8): 531-543, 2020 08.
Article
in English
| MEDLINE | ID: covidwho-600931
ABSTRACT
Recent advances in the pathophysiologic understanding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has indicated that patients with severe coronavirus disease 2019 (COVID-19) might experience cytokine release syndrome (CRS), characterized by increased interleukin (IL)-6, IL-2, IL-7, IL-10, etc. Therefore, the treatment of cytokine storm has been proposed as a critical part of rescuing severe COVID-19. Several of the cytokines involved in COVID-19 employ a distinct intracellular signaling pathway mediated by Janus kinases (JAKs). JAK inhibition, therefore, presents an attractive therapeutic strategy for CRS, which is a common cause of adverse clinical outcomes in COVID-19. Below, we review the possibilities and challenges of targeting the pathway in COVID-19.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Coronavirus Infections
/
Betacoronavirus
/
Cytokine Release Syndrome
Type of study:
Prognostic study
Limits:
Animals
/
Humans
Language:
English
Journal:
Trends Pharmacol Sci
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS